Ascendis Pharma

ASND

Equity

ISIN US04351P1012 / Valor 26912602

NASDAQ (2024-11-20)

USD 124.38-0.05%

Ascendis Pharma
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Ascendis Pharma, founded in 2007, is a biopharmaceutical company based in Copenhagen, Denmark, that specializes in developing innovative therapies for rare endocrine diseases. The company is publicly traded on the Nasdaq since 2015 and has a global presence with employees dedicated to improving patients' lives. In 2018, Ascendis Pharma formed VISEN Pharmaceuticals to focus on endocrinology and granted exclusive rights to develop and commercialize its rare disease therapies in Greater China. Key products include TransCon hGH, TransCon PTH, and TransCon CNP.

Summarized from source with an LLMView SourceSector: Technology

Revenue Growth

Ascendis Pharma reported a significant increase in revenue for the first quarter of 2024, totaling €95.9 million compared to €33.6 million in the same period of 2023. This growth was driven by higher commercial sales of products, which more than doubled year-over-year.

Operating Expenses

Operating expenses for Ascendis Pharma in Q1 2024 were €137 million, a notable decrease from the €172.7 million reported in Q1 2023. This reduction in expenses reflects the company's efforts to streamline operations and improve cost efficiency.

Net Loss

Despite the increase in revenue, Ascendis Pharma reported a net loss of €131 million for the first quarter of 2024, compared to a net loss of €110.9 million in the same period of the previous year. The increased loss was primarily due to higher finance expenses.

Cash Position

As of March 31, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €320 million, down from €392.2 million as of December 31, 2023. The decrease in cash reserves is attributed to ongoing investments in research and development and other operational activities.

SKYTROFA Revenue

Revenue from SKYTROFA, Ascendis Pharma's growth hormone product, more than doubled in the first quarter of 2024, reaching €65 million. This represents a 106% year-over-year increase, reflecting a steady rise in the number of treated patients.

Summarized from source with an LLMView Source

Key figures

32.7%1Y

-16.4%3Y

5.77%5Y

Performance

41.6%1Y

53.5%3Y

49.2%5Y

Volatility